APA (7th ed.) Citation

A, R., F, v. K., R, W., M, P., W, U., & J, S. (2014). Assessment of nonischemic fibrosis in hypertrophic cardiomyopathy: Comparison of gadopentetate dimeglumine and gadobenate dimeglumine for enhanced cardiovascular magnetic resonance imaging. Journal of magnetic resonance imaging : JMRI, 39(5), 1153. https://doi.org/10.1002/jmri.24264

Chicago Style (17th ed.) Citation

A, Rudolph, von Knobelsdorff-Brenkenhoff F, Wassmuth R, Prothmann M, Utz W, and Schulz-Menger J. "Assessment of Nonischemic Fibrosis in Hypertrophic Cardiomyopathy: Comparison of Gadopentetate Dimeglumine and Gadobenate Dimeglumine for Enhanced Cardiovascular Magnetic Resonance Imaging." Journal of Magnetic Resonance Imaging : JMRI 39, no. 5 (2014): 1153. https://doi.org/10.1002/jmri.24264.

MLA (9th ed.) Citation

A, Rudolph, et al. "Assessment of Nonischemic Fibrosis in Hypertrophic Cardiomyopathy: Comparison of Gadopentetate Dimeglumine and Gadobenate Dimeglumine for Enhanced Cardiovascular Magnetic Resonance Imaging." Journal of Magnetic Resonance Imaging : JMRI, vol. 39, no. 5, 2014, p. 1153, https://doi.org/10.1002/jmri.24264.